{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Long-acting+beta2-agonist+and+Inhaled+corticosteroids+%28LABA+and+ICS%29",
    "query": {
      "intervention": "Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T07:21:32.461Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02175771",
      "title": "Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Persistent Asthma"
      ],
      "interventions": [
        {
          "name": "Fp MDPI",
          "type": "DRUG"
        },
        {
          "name": "FS MDPI",
          "type": "DRUG"
        },
        {
          "name": "FLOVENT HFA",
          "type": "DRUG"
        },
        {
          "name": "ADVAIR DISKUS",
          "type": "DRUG"
        },
        {
          "name": "albuterol/salbutamol HFA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 758,
      "start_date": "2014-07",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-10-10T07:21:32.461Z",
      "location_count": 101,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02175771"
    },
    {
      "nct_id": "NCT01691547",
      "title": "A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "UMEC /VI",
          "type": "DRUG"
        },
        {
          "name": "UMEC",
          "type": "DRUG"
        },
        {
          "name": "VI",
          "type": "DRUG"
        },
        {
          "name": "FF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2012-12-17",
      "completion_date": "2013-03-08",
      "has_results": false,
      "last_update_posted_date": "2017-07-26",
      "last_synced_at": "2026-10-10T07:21:32.461Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01691547"
    },
    {
      "nct_id": "NCT04718389",
      "title": "A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "GSK3511294 (Depemokimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Benralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of care (SoC)",
          "type": "DRUG"
        },
        {
          "name": "Pre-filled Syringes (PFS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1717,
      "start_date": "2021-01-26",
      "completion_date": "2025-09-14",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-10T07:21:32.461Z",
      "location_count": 119,
      "location_summary": "Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04718389"
    },
    {
      "nct_id": "NCT06372496",
      "title": "Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate",
          "type": "DRUG"
        },
        {
          "name": "Inhaled corticosteroids/long-acting beta-2 agonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1358,
      "start_date": "2024-04-16",
      "completion_date": "2027-06-14",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-10T07:21:32.461Z",
      "location_count": 36,
      "location_summary": "Centreville, Alabama • Little Rock, Arkansas • Newport Beach, California + 31 more",
      "locations": [
        {
          "city": "Centreville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06372496"
    },
    {
      "nct_id": "NCT04138758",
      "title": "Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Tiotropium bromide + Olodaterol",
          "type": "DRUG"
        },
        {
          "name": "LABA/ICS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 42953,
      "start_date": "2019-11-01",
      "completion_date": "2019-11-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-15",
      "last_synced_at": "2026-10-10T07:21:32.461Z",
      "location_count": 1,
      "location_summary": "Watertown, Massachusetts",
      "locations": [
        {
          "city": "Watertown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04138758"
    },
    {
      "nct_id": "NCT02105974",
      "title": "Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1621,
      "start_date": "2014-04-07",
      "completion_date": "2015-07-08",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-10-10T07:21:32.461Z",
      "location_count": 17,
      "location_summary": "Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Sunset",
          "state": "Louisiana"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02105974"
    },
    {
      "nct_id": "NCT01312961",
      "title": "Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Dupilumab)",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone/Salmeterol combination therapy",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Albuterol",
          "type": "DRUG"
        },
        {
          "name": "Levalbuterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 104,
      "start_date": "2011-03",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2017-06-08",
      "last_synced_at": "2026-10-10T07:21:32.461Z",
      "location_count": 50,
      "location_summary": "Anaheim, California • Long Beach, California • Los Angeles, California + 42 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01312961"
    },
    {
      "nct_id": "NCT04184297",
      "title": "Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tiotropium and Olodaterol (Tio+Olo)",
          "type": "DRUG"
        },
        {
          "name": "Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 27190,
      "start_date": "2019-11-01",
      "completion_date": "2019-11-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-15",
      "last_synced_at": "2026-10-10T07:21:32.461Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04184297"
    }
  ]
}